The INCA Annual General Meeting (AGM) 2021 convened the full INCA Membership on March 23rd to reflect on the reported achievements in 2020 and build on 2021 priorities and plans. In its capacity of an umbrella organization, INCA represents 26 patient advocacy and research groups from around the world and works continuously under its three strategic pillars: raising awareness about neuroendocrine cancers, securing patient access to optimal treatment and care, and advancing neuroendocrine cancer research. The elections for Board of Directors and President-Elect also took place during the AGM. Jackie Herman, Christine Rodien-Louw and Dirk Van Genechten have been re-elected to serve for an additional term. They have joined their fellow Board Members Catherine Bouvier, Mark McDonnell, Yoshiyuki Majima and Simone Leyden to keep on developing the organization with drive and dedication in order to help improve outcomes for NET patients, no matter where they live. INCA is delighted to announce that Mark McDonnell is the new INCA President-Elect. He will begin serving his two-year term as INCA President in 2022.